!

12-16-04

3/90

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: Unassigned
Roland BUELOW, et al.) Art Unit: 1645
Application Serial No. 10/774,208) Attorney's Docket No. 39691-0002A
Filed: February 5, 2004	Customer No. 25213
For: SUPPRESSION OF ENDOGENOUS IMMUNOGLOBULIN EXPRESSION IN TRANSGENIC NON-HUMAN ANIMALS EXPRESSING HUMANIZED OR HUMAN ANTIBODIES))))

EXPRESS MAIL LABEL NO. <u>EL 993 687 411 US</u> DATE MAILED: DECEMBER 14, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication, except U.S. patents and patent application publications (1276 OG 55), is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §§ 1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			
	(1) contin	It is being filed within 3 months of the application filing date and is other than a nued prosecution application under § 1.53(d)	
	(2)	It is being filed within 3 months of entry of a national stage	
\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits	

\sim	n	
 U.	ĸ	••

		(4) It is being filed before to request for continued examination	he mailing of a first Office Action after the filing of a on under § 1.114.	
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Off action on the merits, but before the mailing date of the earlier of a final office action under §1.00 or a notice of allowance under §1.311, then:			
		a certification as specified in §1	.97(e) is provided below; or	
		a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.		
		being filed after the mailing date of the earlier of a final allowance under §1.311, but before payment of the issue		
	A.	a certification as specified in §1	.97(e) is completed below; and	
	B.	a petition under 37 C.F.R. §1.97 submitted herewith; and	(d) requesting consideration of this statement is	
	C.	a fee of \$180.00 as set forth in § the payment of other papers file	1.17(i)(1) is authorized below, enclosed, or included with d together with this statement.	
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39691-0002A).			
			Respectfully submitted,	
Dated:	Decem	iber 14, 2004	By: (1) (m)	

HELLER EHRMAN WHITE & MCAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Telephone: (650) 324-7000 / Facsimile: (650) 324-0638

Ginger R. Dreger (Reg. No. 33,055)

STATEMENT 3		ATTY. DOCKET NO.: 39691-0002A		SERIAL NO.: 10/774,208				
P10-1449			APPLICANT: Roland BUELOW, et al.					
			FILING DATE: February 5, 2004		GROUP: 1645			
		U.	S. PATENT DOCUMENT	rs_				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILIN	G DATE	
	5,298,420	03/29/1994	Chang, Tse W.	435	240.27		2-10-1	
		FOR	EIGN PATENT DOCUME	NTS		_		
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRAN	TRANSLATION	
INITIALS						YES	NO	
	WO 02/12437	02/14/2002	PCT	C12N				
	WO 92/03918	03/19/1992	PCT	A01H	1/00			
	OTHER D	OCUMENTS	(Including Author, Title, Da	te, Pertinent Pa	ages, Etc.)			
			IgM Allotype Suppression on eterozygous F1 Mice", Develo					
	Lalor, P. A., et al., "Permanent Alteration of the Murine LY-1 B Repertoire Due to Selective Depletion of LY-1 B Cells in Neonatal Animals", European Journal of Immunology, Vol. 19, No. 3, pp. 501-506, 1989.							
	Lanning, D. K., et al., " Analysis of the 3' Cμ Region of the Rabbit Ig Heavy Chain Locus", Gene: An International Journal on Genes and Genomes, Vol. 309, No. 2, pp. 135-144, 2003.							
	Ratcliffe, M. J. H., et al., "Allotype Suppression in the Chicken III. Analysis of the Recovery from Suppression by Neonatally Injected or Maternal Antibodies", European Journal of Immunology, Vol. II, pp 301-306, 1981.							
EXAMINER	NER DATE CONSIDERED							
								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.